The ongoing COVID-19 pandemic is making its way in each and every country. Amidst, doctors, drug makers and scientists around the globe are continuously on their toes to make the vaccine that will free the world from the pressure. From garlic cloves to hot water, many remedies are being used by people to protect them against coronavirus. Governments are relying on tactics like quarantines, social distancing, and lockdowns while healthcare organizations are using oxygen and fever reducers, like ibuprofen to treat people. But there is no vaccine or a confirmed treatment for coronavirus.
After weeks of the coronavirus outbreak, Chinese scientists sequenced the virus’s genome and shared it with the world. And then the structure of the virus was revealed. The scientists believe that there is a way to put a stop on this outbreak using this information. Coalition for Epidemic Preparedness Innovations, or CEPI, a public-private partnership that launched in 2017 is one of the most prominent and large sponsors of various international vaccine researches for coronavirus. CEPI is partnering with different companies and is providing them award grants for swift vaccine development targeting emerging threats that the pharma companies would otherwise ignore. US government financing — particularly through the Biomedical Advanced Research and Development Authority (BARDA) — has also simplified the process for several manufacturers.
Following are the potential vaccines, drugs, and treatment for coronavirus that are being developed by various organizations:
- The Vaccine Research center at the National Institute of Allergy and Infectious Diseases has been studying the molecular structure of family viruses that belongs to MERS, SARS, and coronavirus. They are testing the mRNA-1273 vaccine that instructs cells to make particular proteins which can be used as a treatment for coronavirus. The idea is that mRNA vaccines may be more effective than older approaches and lead to faster, cheaper development. And because they’re not using live viruses they’re also theoretically healthier. So if approved, mRNA-1273 will be the first human-licensed mRNA vaccine and mark the debut of new, fast-to-develop technology for vaccines.
- A CEPI grant was awarded to the biotech company Inovio Pharmaceuticals and its partner Beijing Advaccine Biotechnology to develop a COVID-19 candidate for the vaccine, INO-4800. INO-4800 is in the preclinical development process, so it hasn’t been tested in humans yet. The group plans to study humans later this year.
- The biotech company CureVac is also working on an mRNA vaccine sponsored by the CEPI, which would function in a manner close to the one being produced by NIAID. Company officials have said they expect their vaccine to be available as early as dropping this year.
- With the aid of BARDA, Johnson & Johnson’s Janssen is developing a vector-based vaccine, a process that has led to the successful Ebola vaccine. Practically, it is based on a non-replicative virus (or viral vector) with some genetics of coronavirus applied to it. The vaccine will be injected into a person’s body, where a protein is formed by the injected virus. If the protein shapes properly (and gets the right shape) it may induce an immune response. And the virus used as a vector can’t make anybody sick — but this vaccine is only in the preclinical phase of testing, meaning it hasn’t been tested in humans yet. If the protein shapes properly (and gets the right shape) it may induce an immune response. And the virus used as a vector can’t make anybody sick — but this the vaccine is only in the preclinical phase of testing, meaning it hasn’t been tested in humans yet.